Browse by Poster Presenter

Type here to filter the list

R
Rabino, Martina

Department of Oncology, University of Turin
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Martina Rabino
Favorite
Raciborska, Anna

Mother and Child Institute, Department of Oncology and Surgical Oncology for Children and Youth
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Anna Raciborska
Favorite
Radaelli, Stefano

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Stefano Radaelli
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Stefano Radaelli
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Stefano Radaelli
Favorite
Rafail, Stavros

Adaptimmune
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Stavros Rafail
Favorite
Rahimizadeh, Pegah

McGill University
(P 240) GLYCOSYLATION SITES IN MOLECULAR DRIVERS OF SARCOMA
Pegah Rahimizadeh
Favorite
Raja, Anand

Cancer Institute (WIA)
(P 017) CLINICAL PROGRESSION ON NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EXTREMITY OSTEOSARCOMA
Anand Raja
Favorite
(P 093) TIME TO TREATMENT INITIATION IN PRIMARY EXTREMITY SARCOMA: AN ANALYSIS OF DATABASE FROM A REGIONAL CANCER CENTRE OF LOW/MIDDLE INCOME COUNTRY
Anand Raja
Favorite
Raj, Rohit

James Cancer Hospital / The Ohio State University
(P 200) CLINICAL CHARACTERISTICS, PATTERNS OF CARE, AND TREATMENT OUTCOMES OF RADIATION-ASSOCIATED SARCOMAS
Rohit Raj
Favorite
Rakheja, Dinesh

University of Texas Southwestern Medical Center
(P 104) INFANTILE EXTRARENAL SPINDLE CELL MESENCHYMAL NEOPLASMS WITH TARGETABLE EGFR KINASE DOMAIN DUPLICATIONS
Dinesh Rakheja
Favorite
Ramos, Rafael

HU Son Espases
(P 135) PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Rafael Ramos
Favorite
Rampello, Nicolò

Sarcoma Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Nicolò Rampello
Favorite
Ranallo, Nicoletta

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Nicoletta Ranallo
Favorite
Randall, Lor

University of California, Davis/Orthopaedic Surgery
(P 095) A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT
Lor Randall
Favorite
(P 175) FIBRIN-ALGINATE INTERPENETRATING NETWORK HYDROGELS AS BIOMIMETIC PLATFORMS TO STUDY OSTEOSARCOMA
Lor Randall
Favorite
(P 251) TARGETING SOFT TISSUE SARCOMA CANCER STEM CELLS IMPROVES DOXORUBICIN SENSITIVITY IN VITRO
Lor Randall
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Lor Randall
Favorite
Ranft, Andreas

University Hospital Essen, Pediatrics III, Essen, Germany
(P 040) TWO RARE SIDES OF ONE RARE DISEASE: EWING SARCOMA WITH AND AS SECONDARY MALIGNANCIES FROM THE EPIDEMIOLOGICAL AND CLINICAL ANALYSIS OF AN INTERNATIONAL TRIAL REGISTRY
Andreas Ranft
Favorite
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Andreas Ranft
Favorite
Rankin, Kenneth

North of England Bone and Soft Tissue Tumour Service, Newcastle upon Tyne Hospitals NHS Foundation Trust and Translational and Clinical Research Institute, Newcastle University, UK
(P 172) DEVELOPMENT OF A TARGETED DUAL-MODALITY RADIOIMMUNOCONJUGATE FOR IMAGE GUIDED SARCOMA SURGERY
Kenneth Rankin
Favorite
Rao, Arvind

University of Michigan
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Arvind Rao
Favorite
Rao, Pranathi

School of Medicine, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Pranathi Rao
Favorite
Rascon, Jelena

Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius University
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Jelena Rascon
Favorite
Ratan, Ravin

The University of Texas MD Anderson Cancer Center
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Ravin Ratan
Favorite
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Ravin Ratan
Favorite
Rathore, Richa

Natera, Inc
(P 047) FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Richa Rathore
Favorite
Rauh, Daniel

Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Daniel Rauh
Favorite
Raut, Chandrajit

Brigham and Women’s Hospital/Harvard Medical School
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Chandrajit Raut
Favorite
(P 214) EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Chandrajit Raut
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Chandrajit Raut
Favorite
Ravikumar, Visweswaran

University of Michigan
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Visweswaran Ravikumar
Favorite
Ravi, Vinod

The University of Texas MD Anderson Cancer Center
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Vinod Ravi
Favorite
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Vinod Ravi
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Vinod Ravi
Favorite
Ray-Coquard, Isabelle

Department of Medical Oncology, Centre Léon Bérard,
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Isabelle Ray-Coquard
Favorite
Raza, Shaan

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Shaan Raza
Favorite
Reaman, Gregory

US Food and Drug Administration
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Gregory Reaman
Favorite
Recine, Federica

Medical Oncology Unit, Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Federica Recine
Favorite
Reddy, Madhusudan

Cancer Institute (WIA)
(P 017) CLINICAL PROGRESSION ON NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EXTREMITY OSTEOSARCOMA
Madhusudan Reddy
Favorite
Redondo, Andres

HU La Paz
(P 135) PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Andres Redondo
Favorite
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Andres Redondo
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Andres Redondo
Favorite
Reed, Damon

Moffitt Cancer Center
(P 019) COUMERMYCIN-A1 (CA1) IDENTIFIED AS A FIRST-IN-CLASS CDC45-MCM-GINS HELICASE INHIBITOR OFFERING THERAPEUTIC POTENTIAL FOR OSTEOSARCOMA TREATMENT
Damon Reed
Favorite
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Damon Reed
Favorite
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Damon Reed
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Damon Reed
Favorite
Regan, Katie

The Life Raft Group
(P 110) PHASE I RESULTS FROM A MULTI-PHASE COMPREHENSIVE GENOMIC SEQUENCING TUMOR STUDY IN GASTROINTESTINAL STROMAL TUMOR PATIENTS
Katie Regan
Favorite
Regan, Olivia

The Life Raft Group
(P 110) PHASE I RESULTS FROM A MULTI-PHASE COMPREHENSIVE GENOMIC SEQUENCING TUMOR STUDY IN GASTROINTESTINAL STROMAL TUMOR PATIENTS
Olivia Regan
Favorite
Reguera Puertas, Pablo

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Pablo Reguera Puertas
Favorite
Reguero-Callejas, María Eugenia

Department of Pathology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
María Eugenia Reguero-Callejas
Favorite
Reichardt, Peter

Helios Klinikum Berlin-Buch
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Peter Reichardt
Favorite
Reich, Steven

Monopar Therapeutics, Inc.
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Steven Reich
Favorite
Reid, Moya

University of Florida College of Pharmacy
(P 256) TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA
Moya Reid
Favorite
Reijers, Sophie

Nederlands Cancer Institute
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Sophie Reijers
Favorite
Reinecke, James

Nationwide Children's Hospital
(P 027) LEPTOMENINGEAL ENHANCEMENT WITH NEUROLOGIC CHANGES IN PEDIATRIC BONE SARCOMA PATIENTS: A DIAGNOSTICAL CHALLENGE
James Reinecke
Favorite
Rekhi:, Bharat

Tata Memorial Centre
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Bharat Rekhi:
Favorite
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Bharat Rekhi:
Favorite
Renne, Lorenzo Salvatore

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy. Department of Pathology, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Lorenzo Salvatore Renne
Favorite
Renne, Lorenzo Salvatore

Humanitas Research Hospital
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Lorenzo Salvatore Renne
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Lorenzo Salvatore Renne
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Lorenzo Salvatore Renne
Favorite
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Lorenzo Salvatore Renne
Favorite
Renne, Salvatore

Humanitas University
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Salvatore Renne
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Salvatore Renne
Favorite
Ren, Tingting

Peking University People’s Hospital
(P 021) DISTINCT GENOMIC FEATURES BETWEEN OSTEOSARCOMAS FIRSTLY METASTASING TO BONE AND TO LUNG
Tingting Ren
Favorite
Repass, Matthew

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Matthew Repass
Favorite
Requena-Aguilar, Javier

Hospital Universitario de Jaén
(P 083) PERFORMANCE OF THE MESENCHYMAL TUMOR COMMITTEE IN A SMALL HOSPITAL IN SOUTHERN SPAIN
Javier Requena-Aguilar
Favorite
Revon-Riviere, Gabriel

Hospital for Sick Children and University of Toronto
(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Gabriel Revon-Riviere
Favorite
Reyners, Anna

University medical center Groningen
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Anna Reyners
Favorite
Rhines, Laurence

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Laurence Rhines
Favorite
Ribeiro, Mauricio Fernando

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Mauricio Fernando Ribeiro
Favorite
Ricke, Jens
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Jens Ricke
Favorite
Riedel, Richard

Duke Cancer Institute, Duke University Medical Center
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Richard Riedel
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Richard Riedel
Favorite
Rieth, John

University of Iowa Hospitals & Clinics
(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
John Rieth
Favorite
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
John Rieth
Favorite
Righi, Alberto

Deapartment of Pathology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Alberto Righi
Favorite
Rincón, Inmaculada

Hospital Virgen del Rocio
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Inmaculada Rincón
Favorite
Rini, Francesca

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Francesca Rini
Favorite
Rios, Maria

Nancy
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Maria Rios
Favorite
Rioux, Patrice

Monopar Therapeutics, Inc.
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Patrice Rioux
Favorite
Riva, Nada

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Nada Riva
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Nada Riva
Favorite
Rivard, Justin

University of Manitoba
(P 088) RETHINKING THE MANAGEMENT OF AGGRESSIVE ANGIOMYXOMA: A REPORT FROM FOUR CANADIAN SARCOMA CENTRES.
Justin Rivard
Favorite
Rivera-Puig, Pedro

Pittsburgh Veterinary Specialty & Emergency Center
(P 025) INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Pedro Rivera-Puig
Favorite
Rivoltini, licia

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
licia Rivoltini
Favorite
Riyahi, Nikan

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Nikan Riyahi
Favorite
Roach, Tyler

James Cancer Hospital / The Ohio State University
(P 200) CLINICAL CHARACTERISTICS, PATTERNS OF CARE, AND TREATMENT OUTCOMES OF RADIATION-ASSOCIATED SARCOMAS
Tyler Roach
Favorite
Robba, Tiziana

Radiology Service, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Tiziana Robba
Favorite
Roberts, Kristofer

Mayo Clinic
(P 201) LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Kristofer Roberts
Favorite
Robertson-Tessi, Mark

Moffitt Cancer Center
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Mark Robertson-Tessi
Favorite
Roberts, Ryan

Division of Hematology and Oncology, Nationwide Children’s Hospital, Department of Pediatrics, The Ohio State University Wexner College of Medicine
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Ryan Roberts
Favorite
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Ryan Roberts
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Ryan Roberts
Favorite
Robinson, Chandler

Monopar Therapeutics, Inc.
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Chandler Robinson
Favorite
Robinson, Denise

The EHE Foundation
(P 194) THE EHE BIOBANK: PATIENTS POWERING RARE CANCER MODEL DEVELOPMENT & TRANSLATIONAL RESEARCH
Denise Robinson
Favorite
Robinson, Myra

Atrium Health/Levine Cancer Institute
(P 261) CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH DESMOID TUMORS: A LARGE SINGLE INSTITUTION RETROSPECTIVE SERIES
Myra Robinson
Favorite
Robinson, Steven

Mayo Clinic
(P 020) DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
Steven Robinson
Favorite
(P 278) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Steven Robinson
Favorite
Robin, Yves-Marie

Department of Biopathology, Centre Oscar Lambret
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Yves-Marie Robin
Favorite
Roca, Maria Jose

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Maria Jose Roca
Favorite
Rodríguez-Garrote, Mercedes

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Mercedes Rodríguez-Garrote
Favorite
Rodrigues, Caroline

CanSaRCC, Princess Margaret Cancer Centre
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Caroline Rodrigues
Favorite
Roesler, Kimberly

Rutgers Robert Wood Johnson General Surgery Department
(P 202) LONG-TERM EXPERIENCE WITH INTRAOPERATIVE ELECTRON RADIATION THERAPY BOOST IN EXTREMITY SARCOMA
Kimberly Roesler
Favorite
Roets, Evelyne

Antoni Van Leeuwenhoek hospital & Dutch Sarcoma Patient organisation
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Evelyne Roets
Favorite
(P 319) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS; PROTOCOL FOR A SYSTEMATIC REVIEW
Evelyne Roets
Favorite
Romagosa, Cleofé

Hospital vall de hebron
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Cleofé Romagosa
Favorite
Rompou, Vaia

The Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Vaia Rompou
Favorite
Rose, Brandon

University of Miami/Sylvester Comprehensive Cancer Center
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Brandon Rose
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Brandon Rose
Favorite
Rosenbaum, Evan

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Evan Rosenbaum
Favorite
Rosenberg, Andrew

Sylvester Comprehensive Cancer Center
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Andrew Rosenberg
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Andrew Rosenberg
Favorite
Rose, Peter

Mayo Clinic
(P 278) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Peter Rose
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Peter Rose
Favorite
(P 302) SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Peter Rose
Favorite
Rosero-Rodríguez, Diana

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Diana Rosero-Rodríguez
Favorite
Rossen, Philip B.

Department of Oncology, Aarhus University Hospital
(P 120) THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Philip B. Rossen
Favorite
Ross, Evelyn

Fox Chase Cancer Center
(P 221) SURGICAL OUTCOMES OF NEOADJUVANT THERAPY FOR GASTROINTESTINAL STROMAL TUMORS: A SINGLE INSTITUTION ANALYSIS
Evelyn Ross
Favorite
Roszik, Jason

The University of Texas MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Jason Roszik
Favorite
(P 269) LANDSCAPE OF GENOMIC ALTERATIONS IN 115 PATIENTS WITH DESMOID FIBROMATOSIS IN THE AACR GENIE REAL WORLD DATABASE: CLINICAL IMPLICATIONS
Jason Roszik
Favorite
Rothschild, Sara

The Life Raft Group
(P 110) PHASE I RESULTS FROM A MULTI-PHASE COMPREHENSIVE GENOMIC SEQUENCING TUMOR STUDY IN GASTROINTESTINAL STROMAL TUMOR PATIENTS
Sara Rothschild
Favorite
Rottgers, S. Alex

Johns Hopkins All Children's Hospital
(P 305) THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
S. Alex Rottgers
Favorite
Royes, Brittany

University of Pittsburgh Medical Center
(P 046) EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Brittany Royes
Favorite
Rubinstein, Maria

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Maria Rubinstein
Favorite
Rub, Jonathan

MSKCC
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Jonathan Rub
Favorite
Rufian, Sebastian

Hospital universitario reina Sofía
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Sebastian Rufian
Favorite
Ruiz-Soto, Rodrigo

Deciphera Pharmaceuticals, LLC
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Rodrigo Ruiz-Soto
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Rodrigo Ruiz-Soto
Favorite
Rupprecht, Gabrielle

Department of Medicine, Duke University
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Gabrielle Rupprecht
Favorite
Rushing, Teresa

Children's Hospital Los Angeles
(P 151) CLINICAL PRESENTATION OF OSTEOSARCOMA PATIENTS WITH ACUTE METHOTREXATE TOXICITY TREATED WITH GLUCARPIDASE
Teresa Rushing
Favorite
Ruspi, Laura

Sarcoma, Melanoma and Rare Tumors Surgery Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Laura Ruspi
Favorite
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Laura Ruspi
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Laura Ruspi
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Laura Ruspi
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Laura Ruspi
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Laura Ruspi
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Laura Ruspi
Favorite
Russo, Pierluigi

Italian Medicines Agency, Rome, Italy
(P 162) PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Pierluigi Russo
Favorite
Rutkowski, Piotr

Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Piotr Rutkowski
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Piotr Rutkowski
Favorite
(P 166) SARCOMA BRAIN METASTASES: EXPERIENCE AT A SINGLE INSTITUTION
Piotr Rutkowski
Favorite
(P 168) SYSTEMIC INFLAMMATION INDEX (SII) AS INDEPENDENT PREDICTIVE FACTOR IN PATIENTS WITH L-SARCOMA TREATED WITH TRABECTEDIN - ANALYSIS OF REAL-WORLD EVIDENCE FROM A REFERENCE CENTER
Piotr Rutkowski
Favorite
(P 169) WHAT IS THE MOSTAPPROPRIATE STUDY ENDPOINT FOR PHASE IICLINICAL TRIALS IN SOFT TISSUE SARCOMA? - CHARACTERISTIC OF THE CURRENT LANDSCAPE OF PHASE II TRIALS
Piotr Rutkowski
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Piotr Rutkowski
Favorite
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Piotr Rutkowski
Favorite
Ryan, Christopher

Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Christopher Ryan
Favorite
Ryu, Hyang Joo

Severance Hospital
(P 265) DEVELOPMENT OF THERAPEUTIC STRATEGY FOR DESMOID TUMOR WITH NOVEL PATIENT-DERIVED PRECLINICAL MODEL
Hyang Joo Ryu
Favorite